Back to top

Image: Bigstock

Compared to Estimates, Alcon (ALC) Q2 Earnings: A Look at Key Metrics

Read MoreHide Full Article

Alcon (ALC - Free Report) reported $2.58 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.8%. EPS of $0.76 for the same period compares to $0.74 a year ago.

The reported revenue represents a surprise of -1.29% over the Zacks Consensus Estimate of $2.61 billion. With the consensus EPS estimate being $0.71, the EPS surprise was +7.04%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Net sales by region- International: $1.42 billion versus $1.45 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.7% change.
  • Net sales by region- United States: $1.16 billion versus the two-analyst average estimate of $1.18 billion. The reported number represents a year-over-year change of +1.7%.
  • Net Sales- Total Surgical: $1.46 billion versus the four-analyst average estimate of $1.48 billion. The reported number represents a year-over-year change of +2.3%.
  • Net Sales- Total Vision care: $1.12 billion versus the four-analyst average estimate of $1.13 billion. The reported number represents a year-over-year change of +6%.
  • Net Sales- Total Surgical- Consumables: $777 million compared to the $786.91 million average estimate based on four analysts. The reported number represents a change of +5.6% year over year.
  • Net Sales- Total Surgical- Equipment/other: $222 million versus $232.7 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change.
  • Net Sales- Total Vision Care- Contact lenses: $692 million versus the four-analyst average estimate of $682.51 million. The reported number represents a year-over-year change of +8.8%.
  • Net Sales- Total Vision Care- Ocular health: $430 million versus the four-analyst average estimate of $446.4 million. The reported number represents a year-over-year change of +1.7%.
  • Net Sales- Total Surgical- Implantables: $456 million versus $464.21 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.7% change.
  • Revenues- Other revenues: $19 million versus $17.22 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +35.7% change.

View all Key Company Metrics for Alcon here>>>

Shares of Alcon have returned +1.1% over the past month versus the Zacks S&P 500 composite's +2.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Alcon (ALC) - free report >>

Published in